Zanamivir
| 證據等級: L5 | 預測適應症: 2 個 |
目錄
Zanamivir: From Influenza to Pyelonephritis
One-Sentence Summary
Zanamivir is a neuraminidase inhibitor originally developed for influenza A/B treatment, working by blocking the viral surface enzyme required for virion release. The TxGNN model predicts it may be effective for Pyelonephritis, but currently 0 clinical trials and 0 publications support this specific link, and the evidence pack's own mechanistic review flags the prediction as a likely false positive.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Influenza (neuraminidase inhibitor; no formal license record available — drug not marketed in Germany) |
| Predicted New Indication | Pyelonephritis |
| TxGNN Prediction Score | 99.84% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| Germany Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data from DrugBank is not available for this candidate (flagged as a High-severity data gap). However, the evidence pack's repurposing rationale confirms zanamivir acts exclusively as a neuraminidase inhibitor against influenza virus surface glycoprotein — it has no antibacterial activity of any kind.
Pyelonephritis is a bacterial upper urinary tract infection, most commonly caused by gram-negative organisms such as E. coli. There is no known pharmacological overlap between viral neuraminidase inhibition and bacterial pyelonephritis pathogenesis. The evidence pack itself states that the high TxGNN score likely reflects a knowledge-graph semantic proximity artifact (both indications are broadly linked to "infection") rather than a genuine mechanistic relationship.
A second, lower-ranked prediction ("disorder of tyrosine metabolism," score 99.02%) shows the same pattern: the only supporting literature discusses the H274Y/H275Y neuraminidase resistance mutation, which involves a histidine→tyrosine amino acid substitution — an incidental naming overlap, not a link to inherited tyrosine metabolism disorders (e.g., tyrosinemia). Neither prediction currently has a credible mechanistic or clinical basis.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Germany Market Information
Zanamivir is currently not marketed in Germany, and no authorization records (BfArM license numbers, product names, or approved indication texts) are available in the database.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top prediction (pyelonephritis) has zero supporting clinical trials or literature, and the evidence pack's own mechanistic review assesses the drug–disease link as biologically implausible and likely a knowledge-graph artifact rather than a genuine pharmacological signal. Evidence level is L5, the lowest tier (model prediction only).
To proceed, the following is needed:
- Resolve the blocking data gap (DG001): TFDA/BfArM label warnings and contraindications, required before any S1 safety pre-assessment
- Confirmed mechanism-of-action data from DrugBank (DG002)
- Independent pharmacological or preclinical rationale connecting neuraminidase inhibition to bacterial pyelonephritis, if this candidate is to be pursued further
- Re-evaluation of TxGNN scoring methodology to address potential semantic-proximity false positives for infection-related indications
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.